

**IN THE CLAIMS**

Please cancel claims 1-15, without prejudice. Please add new claims. The following listing of claims replaces all prior listings.

1-15. (Canceled)

16. (New) A compound selected from the group consisting of a phosphonate of an antiviral compound selected from the group consisting of cidofovir, adefovir, cyclic cidofovir and tenofovir, covalently linked to a molecule selected from the group consisting of an alkylglycerol, alkylpropanediol, 1-S-alkylthioglycerol, alkoxyalkanol or alkylethanol, or its pharmaceutically acceptable salt.

17. (New) The compound of claim 16, wherein the antiviral compound is cidofovir.

18. (New) The compound of claim 17, which is covalently linked to an alkylpropanediol.

19. (New) The compound of claim 17, which is covalently linked to an alkylethanol.

20. (New) The compound of claim 17, which is covalently linked to an alkoxyalkanol.

21. (New) The compound of claim 17, which is covalently linked to an alkylglycerol.

22. (New) The compound of claim 17, which is covalently linked to an 1-S-alkylthioglycerol.

23. (New) The compound of claim 16, wherein the antiviral compound is adefovir.

24. (New) The compound of claim 23, which is covalently linked to an alkylpropanediol.
25. (New) The compound of claim 23, which is covalently linked to an alkylethanediol.
26. (New) The compound of claim 23, which is covalently linked to an alkoxyalkanol.
27. (New) The compound of claim 23, which is covalently linked to an alkylglycerol.
28. (New) The compound of claim 23, which is covalently linked to an 1-S-alkylthioglycerol.
29. (New) The compound of claim 16, wherein the antiviral compound is cyclic cidofovir.
30. (New) The compound of claim 29, which is covalently linked to an alkylpropanediol.
31. (New) The compound of claim 29, which is covalently linked to an alkylethanediol.
32. (New) The compound of claim 29, which is covalently linked to an alkoxyalkanol.
33. (New) The compound of claim 29, which is covalently linked to an alkylglycerol.
34. (New) The compound of claim 29, which is covalently linked to an 1-S-alkylthioglycerol.

35. (New) The compound of claim 16, wherein the antiviral compound is tenofovir.
36. (New) The compound of claim 35, which is covalently linked to an alkylpropanediol.
37. (New) The compound of claim 35, which is covalently linked to an alkylethenediol.
38. (New) The compound of claim 35, which is covalently linked to an alkoxyalkanol.
39. (New) The compound of claim 35, which is covalently linked to an alkylglycerol.
40. (New) The compound of claim 35, which is covalently linked to an 1-S-alkylthioglycerol.
41. (New) The compound of claim 16, wherein the phosphonate is linked through the 3-position of the molecule.
42. (New) The compound of claim 16, wherein the phosphonate is a phosphonate or a methylene phosphonate.
43. (New) The compound of claim 16, wherein the phosphonate of an antiviral compound is covalently linked to an alkylpropanediol.
44. (New) The compound of claim 43, wherein the antiviral compound is cidofovir.
45. (New) The compound of claim 43, wherein the alkylpropanediol is 1-O-hexadecylpropanediol or 1-octadecylpropanediol.

46. (New) The compound of claim 43, wherein the alkylpropanediol is 1-O-hexadecylpropanediol or 1-O-octadecylpropanediol and the antiviral compound is cyclic cidofovir.

47. (New) The compound of claim 43, wherein the alkylpropanediol is 1-O-octadecylpropanediol.

48. (New) The compound of claim 16, wherein the phosphonate of an antiviral compound is covalently linked to an alkylethanol.

49. (New) The compound of claim 48, wherein the antiviral compound is cidofovir.

50. (New) The compound of claim 49, wherein the alkylethanol is 1-O-octadecylethanol.

51. (New) The compound of claim 16, wherein the phosphonate of an antiviral compound is covalently linked to an alkylglycerol.

52. (New) The compound of claim 51, wherein the antiviral compound is cidofovir.

53. (New) The compound of claim 52, wherein the alkylglycerol is a 1-O-alkylglycerol.

54. (New) The compound of claim 52, wherein the alkylglycerol is a 3-O-alkylglycerol.


55. (New) The compound of claim 51, wherein the antiviral compound is cyclic cidofovir.

56. (New) The compound of claim 55, wherein the alkylglycerol is a 1-O-alkylglycerol.


57. (New) The compound of claim 55, wherein the alkylglycerol is a 3-O-alkylglycerol.
58. (New) The compound of claim 51, wherein the antiviral compound is adefovir.
59. (New) The compound of claim 58, wherein the alkylglycerol is a 1-O-alkylglycerol.
60. (New) The compound of claim 58, wherein the alkylglycerol is a 3-O-alkylglycerol.
61. (New) The compound of claim 51, wherein the antiviral compound is tenofovir.
62. (New) The compound of claim 61, wherein the alkylglycerol is a 1-O-alkylglycerol.
63. (New) The compound of claim 61, wherein the alkylglycerol is a 3-O-alkylglycerol.
64. (New) The compound of claim 16, wherein the phosphonate of an antiviral compound is covalently linked to a 1-S-alkylthioglycerol.
65. (New) The compound of claim 64, wherein the antiviral compound is cidofovir.
66. (New) The compound of claim 16, wherein the phosphonate of an antiviral compound is covalently linked to an alkoxyalkanol.
67. (New) The compound of claim 66, wherein the antiviral compound is cidofovir.
68. (New) The compound of claim 66, wherein the alkoxyalkanol is a 1-O-alkylpropane-3-ol.

69. (New)      The compound of claim 68, wherein the antiviral compound is cidofovir.
70. (New)      The compound of claim 68, wherein the antiviral compound is cyclic  
cidofovir.
71. (New)      The compound of claim 68, wherein the antiviral compound is tenofovir.
72. (New)      The compound of claim 68, wherein the antiviral compound is adefovir.
73. (New)      A method for the treatment of a viral disease selected from human  
immunodeficiency virus, influenza, herpes simplex virus, human herpes virus, cytomegalovirus,  
hepatitis B and C virus, Epstein-Barr virus, varicella zoster virus, orthopox virus, ebola virus and  
papilloma virus comprising administering an effective amount of a compound of claim 16  
optionally in a pharmaceutically acceptable carrier.
74. (New)      The method of claim 73 wherein orthopox is selected from variola major  
and minor, vaccinia, smallpox, cowpox, camelpox and monkeypox.
75. (New)      The method of claim 73, wherein the virus is HIV.
76. (New)      The methods of claim 73, wherein the virus is influenza.
77. (New)      The method of claim 73, wherein the virus is herpes.
78. (New)      The method of claim 73, wherein the virus is cytomegalovirus.
79. (New)      The method of claim 73, wherein the virus is hepatitis B.
80. (New)      The method of claim 73, wherein the virus is hepatitis C.
81. (New)      The method of claim 73, wherein the virus is Epstein-Barr virus.

84. (New) The antiviral phosphonate compound of claim 16, having the structure or its pharmaceutically acceptable salt:



- Gray Cary\6404594v1  
101668-221



86. (New) 1-O-octadecylpropanediol-3-cidofovir.
87. (New) 1-O-octadecylethanediol-2-cidofovir.
88. (New) 1-O-hexadecylpropanediol-3-cidofovir
89. (New) 1-O-hexadecylpropanediol-3-cyclic cidofovir.
90. (New) 1-O-octadecylpropanediol-3-cyclic cidofovir.
91. (New) 1-O-octadecylethanediol-2-cyclic cidofovir.
92. (New) 1-O-hexadecylpropanediol-3-adefovir.
93. (New) 1-O-octadecyl-sn-glycero-3-adefovir.
94. (New) A pharmaceutical composition comprising an effective amount of an antiviral phosphonate compound of claims 16 or 84-93 in combination with a pharmaceutically acceptable carrier.